Navigation Links
miR-205 can be responsible for breast cancer
Date:12/21/2012

Over the past couple of years research into miRNAs has become increasingly diversified and attracted a great number of research articles across genetics and medicine. This should hardly come as a surprise to any scientist in the field, especially since it has become clear that miRNAs, a recently discovered class of non-coding RNAS, are represented in nearly all cellular functions and molecular pathways. A growing list of reports demonstrates that microRNAs play a critical role in cancer initiation and progression, and that miRNA alterations are ubiquitous in human cancers. In fact, several studies have shown that miRNAs can act either as tumor suppressors or as oncogenes, and that measurement of miRNA expression in malignancies may have diagnostic implications or otherwise lead to novel treatments of breast cancer.

In the article "Mir-205 modulates acinar size and morphology of transformed breast epithelial cells" which will be released later this week in OncomiRs an open access journal published by Versita, molecular biologists from CEA Saclay and Universit Paris-Sud, led by Prof. Annick Harel-Bellan, studied the microRNAs expression potentially responsible for the abnormal acini formation of breast cancer cells. They observed that the overexpression of the miR-205 influences the morphology of acini, linking this miRNA to breast epithelial cell transformation.

A genome-wide microRNA expression screen comparing non-transformed and tumorigenic MCF10A cell lines identified miR-205 as a potential modifier of acinus size. Forced expression of miR-205 in non-transformed MCF10A cells increased the size of acini, whereas miR-205 antisense oligonucleotides restored a normal morphology. MiR-205 did not modify cell proliferation, but rather inhibited cell death by apoptosis. Moreover, miR-205 targets ZEB1, an inhibitor of E-cadherin. Downregulating E-cadherin restored normal acinar morphology in miR-205 expressing cells, consistent with E-cadherin being involved in the miR-205-dependent acini phenotype.

The researchers further examined critical cellular formation in breast cancer. It has been demonstrated that normal breast epithelial cells form highly organized multi-cellular structures - the breast lobules, terminating in acinar structures called alveoli, which can be mimicked in vitro in three-dimensional (3D) cultures. Moreover, breast epithelial cells self-organize to form "acini". The size and morphology of acini is highly dependent on the degree of cancerous transformation of breast epithelial cells. Transformed cell lines form larger acini than normal cells, and cancer cells do not form normal acini, but instead form much larger aggregates of cells with no well-defined lumen.

Commenting on the research results, Prof. Annick Harel-Bellan notes: ' miR-205 is definitely not a simple tumor-suppressor miRNA in breast as previously believed, but it can be overexpressed in transformed cells and can be responsible for the abnormally large morphology of acini.'

The research highlights the complexity of miR-205 function in breast epithelial cells: miR-205 can act not only as a tumor suppressor, as formerly proposed, but also as an oncogene that favors cell proliferation or represses cell death. "Consequently, the use of miR-205 as a curative miRNA in cancer, as previously suggested by others, should be approached with great caution" observes Harel-Bellan in her article. Without doubt, continuous efforts to identify and describe miRNAs will provide novel insights into breast cancer biology, and will eventually arrange for a new molecular target for alternative treatments.


'/>"/>
Contact: Maria Hrynkiewicz
maria@versita.com
48-660-476-421
Versita
Source:Eurekalert

Related medicine news :

1. University of Hawaii cancer researchers discover gene defect responsible for cancer syndrome
2. Helper T cells, not killer T cells, might be responsible for clearing hepatitis A infection
3. Gene expression improves the definition of a breast cancer subtype
4. Healthy lifestyle during menopause may decrease breast cancer risk later on
5. CWRU School of Medicine researchers discover new molecule linked to late-stage breast cancer
6. The HER2 paradox: HER2-positive stem cells found in HER2-negative breast cancer
7. Study Examines Link Between Breast Cancer and Diabetes
8. Delaying childbirth may reduce risk of an aggressive form of breast cancer
9. Nouvelle Announces Surgical Garments for New Reverse Liposuction Procedure Designed to Replace Breast Implants with Fat
10. To fight incurable metastatic breast cancer, resistance must be broken
11. In vitro study finds digested formula, but not breast milk, is toxic to cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists on ... the flipper will get rich in no time. But what about the buyers of ... for the buyer of a flipped house. An email recently sent to Gary Case ...
(Date:6/28/2017)... , ... June 28, 2017 , ... David B. Sosin, a founding partner ... took over the post of 2nd Vice President for the Illinois State Bar Association ... as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served in ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces ... of the award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer ... as a regional supplier of garden pea seed. As demand grew, the small company ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a Cincinnati ... to insurance assistance and financial planning services, is announcing the commencement of a ... the region facing financial crisis. , Matthew 25: Ministries (M25M) is an international ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... Inc., (Nasdaq: NVAX ) today announced that data ... RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) ... the journal Vaccine (the data contained ... The Company previously announced top line results from ... F Vaccine with the goal of protecting infants from RSV ...
Breaking Medicine Technology: